EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Probiotic supplementation and risk of necrotizing enterocolitis and mortality among extremely preterm infants—the Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial: study protocol for a multicenter, double-blinded, placebo-controlled, and registry-based randomized controlled trial

Probiotische Supplementierung und Risiko für nekrotisierende Enterokolitis und Mortalität bei extrem frühgeborenen Kindern – die PEPS-Studie: Studienprotokoll für eine multizentrische, doppelblinde, placebokontrollierte und registerbasierte randomisierte kontrollierte Studie

Sofia Söderquist Kruth, Carl Willers, Emma Persad, Elisabeth Stoltz Sjöström, Susanne Rautiainen Lagerström, Alexander Rakow

Trials · 12.04.2024 · 25 (1)

DOI: 10.1186/s13063-024-08088-8 ↗

Auf einen Blick

Die PEPS-Studie prüft bei extrem Frühgeborenen Probiotika versus Placebo. Untersucht werden nekrotisierende Enterokolitis und/oder Mortalität als primärer Endpunkt.

Fragestellung

Welche Wirkung hat eine probiotische Supplementierung im Vergleich zu Placebo auf nekrotisierende Enterokolitis und/oder Mortalität bei extrem Frühgeborenen?

Methode

Multizentrische, doppelblinde, placebokontrollierte, registerbasierte randomisierte kontrollierte Studie in Schweden und Dänemark.

Ergebnisse

Die Studie ist als randomisierte kontrollierte Studie mit 1.620 extrem frühgeborenen Kindern geplant. Primärer Endpunkt ist die Inzidenz von nekrotisierender Enterokolitis und/oder Mortalität.

Schlussfolgerung der Autor:innen

Die Studie soll robuste Evidenz zu den Effekten einer probiotischen Supplementierung auf nekrotisierende Enterokolitis, Tod und weitere relevante Endpunkte liefern.

Kernaussagen

  • Studienprotokoll für 1.620 extrem Frühgeborene
  • Probiotika: ProPrems® vs. Placebo
  • Primärer Endpunkt: nekrotisierende Enterokolitis und/oder Mortalität

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Trials, online erschienen am 12.04.2024. Verfasst von Sofia Söderquist Kruth und 5 weiteren Autor:innen. Beteiligte Einrichtung: Women's Health and Allied Health Professional Theme, Karolinska University Hospital, Solna, 17176, Stockholm, Sweden. Hauptthemen laut MEDLINE: Enterocolitis, Necrotizing, Infant, Newborn, Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extremely preterm infants, defined as those born before 28 weeks’ gestational age, are a very vulnerable patient group at high risk for adverse outcomes, such as necrotizing enterocolitis and death. Necrotizing enterocolitis is an inflammatory gastrointestinal disease with high incidence in this cohort and has severe implications on morbidity and mortality. Previous randomized controlled trials have shown reduced incidence of necrotizing enterocolitis among older preterm infants following probiotic supplementation. However, these trials were underpowered for extremely preterm infants, rendering evidence for probiotic supplementation in this population insufficient to date.

Methods

The Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial is a multicenter, double-blinded, placebo-controlled and registry-based randomized controlled trial conducted among extremely preterm infants ( n = 1620) born at six tertiary neonatal units in Sweden and four units in Denmark. Enrolled infants will be allocated to receive either probiotic supplementation with ProPrems® ( Bifidobacterium infantis , Bifidobacterium lactis , and Streptococcus thermophilus ) diluted in 3 mL breastmilk or placebo (0.5 g maltodextrin powder) diluted in 3 mL breastmilk per day until gestational week 34. The primary composite outcome is incidence of necrotizing enterocolitis and/or mortality. Secondary outcomes include incidence of late-onset sepsis, length of hospitalization, use of antibiotics, feeding tolerance, growth, and body composition at age of full-term and 3 months corrected age after hospital discharge.

Discussion

Current recommendations for probiotic supplementation in Sweden and Denmark do not include extremely preterm infants due to lack of evidence in this population. However, this young subgroup is notably the most at risk for experiencing adverse outcomes. This trial aims to investigate the effects of probiotic supplementation on necrotizing enterocolitis, death, and other relevant outcomes to provide sufficiently powered, high-quality evidence to inform probiotic supplementation guidelines in this population. The results could have implications for clinical practice both in Sweden and Denmark and worldwide.

Trial registration

( Clinicaltrials.gov ): NCT05604846

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterocolitis, NecrotizingInfant, Newborn, DiseasesInfantInfant, NewbornHumansInfant, Extremely PrematureScandinavian and Nordic CountriesRegistriesDietary SupplementsRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

Extreme prematurityFeeding toleranceGrowth failureMortalityNecrotizing enterocolitisProbioticsRandomized controlled trial

Autor:innen und Institutionen

  • Women's Health and Allied Health Professional Theme, Karolinska University Hospital, Solna, 17176, Stockholm, Sweden.
  • Department of Women's and Children's Health, Karolinska Institutet, 17177, Stockholm, Sweden.
  • Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 14152, Huddinge, Sweden.
  • Department of Food, Nutrition and Culinary Science, Umeå University, Umeå, Sweden.
  • Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • K2 Medicin, Solna, Karolinska Institutet, Stockholm, Sweden.

Förderung

  • Karolinska Institute

Zitieren

APA

Kruth, S. S., Willers, C., Persad, E., Sjöström, E. S., Lagerström, S. R., & Rakow, A. (2024). Probiotic supplementation and risk of necrotizing enterocolitis and mortality among extremely preterm infants—the Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial: study protocol for a multicenter, double-blinded, placebo-controlled, and registry-based randomized controlled trial. Trials, 25(1). https://doi.org/10.1186/s13063-024-08088-8

Vancouver

Kruth SS, Willers C, Persad E, Sjöström ES, Lagerström SR, Rakow A. Probiotic supplementation and risk of necrotizing enterocolitis and mortality among extremely preterm infants—the Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial: study protocol for a multicenter, double-blinded, placebo-controlled, and registry-based randomized controlled trial. Trials. 2024;25(1). doi:10.1186/s13063-024-08088-8

BibTeX
@article{Kruth2024,
  author = {Kruth, Sofia Söderquist and Willers, Carl and Persad, Emma and Sjöström, Elisabeth Stoltz and Lagerström, Susanne Rautiainen and Rakow, Alexander},
  title = {Probiotic supplementation and risk of necrotizing enterocolitis and mortality among extremely preterm infants—the Probiotics in Extreme Prematurity in Scandinavia (PEPS) trial: study protocol for a multicenter, double-blinded, placebo-controlled, and registry-based randomized controlled trial},
  journal = {Trials},
  year = {2024},
  volume = {25},
  number = {1},
  doi = {10.1186/s13063-024-08088-8}
}
Kostenlos starten →